Abstract
Cancer is the second highest cause of death globally, with about 70% of deaths occurring in low- or middle-income countries, thus calling for efficient cures. Nanotechnology research has evidenced numerous therapeutic innovations that target the tumor tissues either passively or actively. Camptothecin is a potent anticancer drug which has shown appreciable antitumor activity against a broad spectrum of cancers such as breast, ovarian, colon, lung and stomach. Nonetheless, applications of camptothecin are limited by water insolubility, rapid conversion of its bioactive lactone form to inactive carboxylate under physiological conditions, drug resistance and off-target side effects. Here, we review the delivery of camptothecin by active and passive targeting for anticancer activity. We discuss the mechanism of action and the novel targeted drug delivery platforms that have been explored for the delivery of camptothecin for the treatment of solid tumors.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
